In post-weaning swine production where water medication lines deliver multiple agents through metering pumps at 1:100 to 1:200 dosing ratios, Houttuyniae Herba Powder is incorporated into a water-dispersible granule intermediate rather than dry-blended directly into feed. The powder is first screened through a 180 µm sieve to remove fibrous aggregates that would otherwise clog drinking nipple valves in farrowing rooms. The industrial batch record specifies an API inclusion of 120–180 g/kg of granular intermediate, with the remaining mass composed of lactose monohydrate, sodium citrate dihydrate, and povidone K30 as binder. This ratio is established by HPLC-DAD assay to deliver a total flavonoid concentration of not less than 0.8% w/w in the finished granule, measured as quercitrin at 326 nm. Compliance for this oral solution precursor follows the Chinese Veterinary Pharmacopoeia 2020 powdered herb monograph, USP 561 for botanical identity, and VICH GL18(R) for residual solvents if ethanol-water extraction is used before drying. The downstream production process consists of high-shear wet granulation in a 250 L vertical granulator with impeller speed 220 rpm and chopper speed 1,400 rpm, followed by fluid-bed drying at 55–65°C until the loss on drying by USP 731 is ≤ 5.0% w/w. Dried granules are classified through 16-mesh and 60-mesh sieves before packing into 500 g aluminium-foil sachets. The terminal finished product type is a water-dispersible oral granule reconstituted at 10–20 g/L of drinking water for piglets during the post-weaning enteritis risk window; field use on medication lines requires in-line filters of 50 µm to retain residual herb fibers without pump cavitation.

What Drives Mixing Uniformity in Broiler and Layer Premix Carriers Below 0.5 wt% Inclusion?

Low-dose in-feed application of Houttuyniae Herba Powder in poultry production is treated as a microingredient premix, not as a direct feed addition, because the target complete-feed inclusion of 0.3–0.8 kg/tonne corresponds to 300–800 ppm and requires carrier-assisted geometric dilution to avoid segregation in 20 kg premix bags. The API is first blended with precipitated silica at 2.0% w/w as anticaking agent and rice hull meal as carrier in a stepwise ratio of 1:5:25 until a 5% w/w intermediate concentrate is obtained. A horizontal ribbon mixer with a net mixing volume of 500 L is operated at 40 rpm for 12 minutes, and batch release includes CV ≤ 5.0% measured by a 10-point sampling plan, using a 250 µm analytical sieve method for particle-size distribution. Compliance for this premix type is governed by EU Regulation 2019/6 if it is placed on the market as a feed additive, and the raw powder must meet mycotoxin guidance for feed materials under Commission Recommendation 2006/576/EC. The downstream production process requires step-wise dilution before final mixing, with the premix subsequently packed in low-permeability paper-plastic sacks and stored at ≤ 25°C and ≤ 60% RH. The terminal finished product type is a 0.5% w/w poultry in-feed premix for subsequent mixing in complete feed mills; the addition ratio is controlled by marker-based correction per batch because seasonal variation in total flavonoids influences final color and assay.

Injectable Extraction Streams and the Removal of Pyrogenic Polysaccharide Fractions

Parenteral use of Houttuyniae Herba Powder is not a direct dissolution operation; the API serves as an extraction feedstock for aqueous decoction followed by clarification, molecular separation, and aseptic filling. The extraction ratio is maintained at 1:8 to 1:10 w/v in water for injection at 85–95°C for 2 hours, producing a primary liquor that is concentrated under vacuum to a final ratio equivalent to 1 g of crude herb per 2–5 mL of finished injection. The critical quality boundary for this downstream form is not the raw powder addition mass but the soluble marker concentration; typical release criterion is total flavonoids ≥ 0.5 mg/mL and sodium houttuyfonate ≥ 0.2 mg/mL by HPLC-DAD, though published data for this specific configuration is limited and each manufacturing authorization holder must validate the clinical target. Compliance for the injectable route includes USP 71 for sterility, USP 85 for bacterial endotoxins with an acceptance threshold below 0.5 EU/mL, USP 788 for particulate matter, and VICH GL18(R) for any residual ethanol or methanol introduced during extract concentration. The downstream production sequence uses a 0.45 µm prefilter, then a 10 kDa tangential-flow ultrafiltration membrane to remove high-molecular-weight polysaccharides and condensed tannins that contribute to injection-site reactions, followed by terminal 0.22 µm sterilizing filtration into Type I glass vials under ISO 14644-1 Class A laminar airflow. The terminal finished product type is a 10 mL or 20 mL parenteral solution for veterinary use in swine respiratory disease adjunct therapy; operational boundaries include pH adjustment to 5.5–6.5 with sodium hydroxide and storage below 25°C because the volatile decanoyl acetaldehyde marker degrades above 30°C.

When botanical APIs with high fiber and hygroscopicity are compressed into immediate-release tablets, dry-sieving of Houttuyniae Herba Powder through a 150 µm screen precedes pre-blending with microcrystalline cellulose PH 102 and crospovidone before wet granulation with a 5% w/v povidone K30 binder solution. The addition ratio in the core granulation is 320–450 g/kg of final tablet core, corresponding to a 250 mg or 500 mg immediate-release tablet after compression; the chosen range is dictated by the need to balance disintegration time against dose-per-tablet. Granulation is carried out in a 100 L high-shear granulator at 180 rpm impeller speed and 1,200 rpm chopper speed, followed by drying at 50°C in a tray dryer until loss on drying by USP 731 is ≤ 6.0% w/w. Lubrication uses magnesium stearate at 0.5% w/w added before compression on a 16-station rotary tablet press at 12 kN compression force, with hardness maintained between 70 N and 100 N and friability ≤ 1.0% by USP 1216. Compliance for this dosage form falls under current good manufacturing practice for medicated oral solids if labeled as a veterinary medicinal product, and the botanical powder must satisfy USP 561 and microbial limits by USP 61/USP 62 before granulation. The terminal finished product type is an immediate-release tablet for companion animal veterinary practice, packaged in HDPE bottles with desiccant sachets; the main operational boundary is that the dried tablet absorbs moisture above 60% RH and must be coated with a thin hydroxypropyl methylcellulose film to prevent capping during primary packaging.

Ruminant Oral Drench Powders and High-Pectin Matrix Disintegration

For neonatal calf and lamb oral drench applications, Houttuyniae Herba Powder is incorporated into a water-swellable suspension vehicle rather than a dry feed because esophageal groove closure directs the dose to the abomasum and requires a viscosity high enough to prevent rapid sedimentation. The standard slurry contains 80–150 g/L of API in the final drench, with xanthan gum at 1.5 g/L, sodium carboxymethylcellulose at 5.0 g/L, and polysorbate 80 at 0.2% w/v to wet the hydrophobic cuticle of dried herb fragments. The preparation method uses a rotor-stator homogenizer at 1,200 rpm for 15 minutes to shear the fiber bundles, followed by deaeration under 0.08 MPa vacuum to remove entrapped air that would otherwise cause volume displacement in 100 mL dosing pistols. Compliance for the oral drench is assigned under current veterinary medicinal product legislation for oral suspensions, with the raw powder tested for Salmonella absence in 25 g by ISO 6579-1:2017 and for total aerobic microbial count by USP 61. The addition ratio is adjusted batchwise based on the powdered API’s water absorption capacity, which varies from 2.8 mL/g to 3.6 mL/g; this viscosity range of 300–800 mPa·s measured by Brookfield viscometer at 25°C is used as an in-process release limit. The terminal finished product type is a 100 mL or 250 mL oral drench suspension for enteric support in ruminants; the process boundary is that the suspension must be agitated continuously during filling because rapid settling of particles larger than 75 µm would shift the delivered dose.

When a Low-Shear Aquafeed Pellet Premix Incorporates Houttuyniae Herba Powder without Steam Preconditioning

Integrating Houttuyniae Herba Powder into low-shear aquafeed premixes without steam preconditioning requires a cold-blending sequence rather than direct extrusion, because the volatile antimicrobial marker decanoyl acetaldehyde degrades rapidly above 40°C. In aquafeed lines producing sinking pellets for carp and tilapia, the API is generally added as part of a dry vitamin-mineral premix before final conditioning and extrusion, with the inclusion ratio constrained to 0.2–1.0 kg/tonne of complete feed because higher loadings increase pellet expansion and reduce water stability. The cold-mixing stage uses a double-ribbon mixer at 25 rpm for 8 minutes and a maximum product temperature of 40°C; the premix is then transferred through a 500 µm safety sieve to remove stem fragments that would block 1.5 mm pellet die plates of single-screw extruders. Compliance for this application is as a zootechnical feed additive or feed material under EU Regulation 2019/6 and Commission Recommendation 2006/576/EC for mycotoxin control, with the botanical powder dried to ≤ 12% moisture. The downstream process specifies vacuum coating after extrusion only if the pellet is fat-coated, and the finished premix is packed in 10 kg bags with desiccant. The terminal finished product type is a sinking aquafeed premix used at 0.2–1.0 kg/tonne in complete feed, yielding pellets with water stability > 30 minutes by tank immersion test; however, published data for this specific configuration is limited because most aquafeed trials use dried extract rather than raw powder.